{"name":"Arbutus Biopharma","slug":"arbutus","ticker":"ABUS","exchange":"NASDAQ","domain":"arbutusbio.com","description":"Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.","hq":"Warminster, PA","founded":0,"employees":"19","ceo":"William H. Meury","sector":"Hepatitis B / Virology","stockPrice":4.3,"stockChange":-0.01,"stockChangePercent":-0.23,"marketCap":"$848M","metrics":{"revenue":191444992,"revenueGrowth":10054.5,"grossMargin":86.8,"rdSpend":25241000,"netIncome":-33501000,"cash":95226000,"dividendYield":0,"peRatio":5.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"AB-452 patent cliff ($0.0B at risk)","drug":"AB-452","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"AB-729 patent cliff ($0.0B at risk)","drug":"AB-729","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARB-001467","genericName":"ARB-001467","slug":"arb-001467","indication":"Chronic hepatitis B","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TKM-080301","genericName":"TKM-080301","slug":"tkm-080301","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARB-001467","genericName":"ARB-001467","slug":"arb-001467","phase":"phase_2","mechanism":"ARB-001467 is an investigational drug that targets the hepatitis B virus.","indications":["Chronic hepatitis B"],"catalyst":""},{"name":"TKM-080301","genericName":"TKM-080301","slug":"tkm-080301","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Arbutus Biopharma Announces FDA Clearance of IND for AB-729","summary":"The FDA cleared the Investigational New Drug (IND) application for AB-729, a RNAi therapeutic candidate for the treatment of hepatitis B.","drugName":"AB-729","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Arbutus Biopharma Reports Third Quarter 2023 Financial Results","summary":"The company reported revenue of $13.4 million and a net loss of $24.4 million for the third quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Arbutus Biopharma Enters into Collaboration Agreement with Gilead Sciences","summary":"The company entered into a collaboration agreement with Gilead Sciences to develop and commercialize AB-729 for the treatment of hepatitis B.","drugName":"AB-729","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-23","type":"earnings","source":"simplywall.st","summary":"Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st","headline":"Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives","sentiment":"negative"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5uSmtJSmczYUYzS3BJQTJGYXQyRGsxMFlVTG1WYTRxbkd6emUybHN2UG1TTXFhaFJWNHFtZ1JRX0VYMWUwOTkyRzZlLWx5VWw5TFE3Qkg5a24zWTBMMy12TlpTV2FUYThJX2g5WGZvdjVmQQ?oc=5","date":"2026-03-05","type":"patent","source":"investingnews.com","summary":"Moderna Resolves $950M Patent Battle Over COVID-19 Vaccine Tech—Find Out How It Impacts the Industry - investingnews.com","headline":"Moderna Resolves $950M Patent Battle Over COVID-19 Vaccine Tech—Find Out How It Impacts the Industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOVHFPVTRfRVBvQjlyZ2k2T2lqdkNNall5czV3bEE1dy1sZE01OXZ3cHl4aW5XZ0xJYWhBTUUxUUVwR1ZyaXk0UE1ES0FkaXZLa1F2QTRKc1dYV0VVTndyNXlESm5KVU16WUhIS1ZPaTFRYVh2MjNTT2lyaDlvcGt1RnJBNTJ5c3RhQXg3VTh0RkZPUjdRYUtQTklWTExyNFMzNjBPRGZXaHctZ1dSLWtiRWd1bnNPZw?oc=5","date":"2026-03-04","type":"pipeline","source":"The Pharma Letter","summary":"Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter","headline":"Genevant and Arbutus agree $2.25 billion global settlement with Moderna","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQc2hiWUxnRVZ1SU8welFhZGYwUDgycDJpN1BnMnhwR20xWHZCR1loemZzVjRNdHJBVm1XMEFiY0JVemJRMldTTldUYnpydjA5Y3Z1cVpZOUhnS0xvak1iM28zZ28zQ3F3aEIzVzBwT3Y1RnAtWklLcFNHRERwNWlNYi14Z1ExaXB1UFRlcERlTndoeTIwSDAtV2ljaHhkNktoclFSMlR3XzV5eHlaX3U3TA?oc=5","date":"2026-03-03","type":"patent","source":"Stock Titan","summary":"Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan","headline":"Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNd3ZZWi00NG9PWVZ3U2NRaWVyUnhSRzNVd0ZhYjdwWG9hc2ZqSGx1YXhfZ0tDREVvcFRpVjlrcjVMRWpvT3BBVXExT2t6RXlCU3ZndWJacmZ1WldsY1pTSFpJSzJKamNlWi14M2hseTBZVjdFalNpM0FVdWdhNm95bDdpd0JmUTBmZXB4UEcxZUNOZ21sSmswX1lLZFRrV0dERmZfQ2M5ZXI0bFdxcTNyWHNOZzFPbVRMVmtBYmJac04?oc=5","date":"2026-03-03","type":"deal","source":"Stock Titan","summary":"$2.25 billion Moderna deal ends COVID vaccine patent fight - Stock Titan","headline":"$2.25 billion Moderna deal ends COVID vaccine patent fight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQZDdPN081XzJ3SDNOaGFxR3pCeXdTd3hXU1JqV0NGWXBYUk5qbEEyZ19kZ3pGZ3lLTFh6MS0tWWhKTTZQY3VNUVo4dlVRWDdESGRJS041Z3A0NHR2N0daTGdoWHZCb1gwX3VfZExLQkkyMTBWX19UZ3U4NWZJaFBTMFhFRjBkUFBnNkJOTm5hVmJ4Yk53Z0FXN1o4X3ZNdTA1a1NjZjZkOUZCUlluRUl3d011Mk1iTmVGN2Rtbk1US09Ya0I0TURuaEFocEk?oc=5","date":"2026-03-03","type":"patent","source":"MarketWatch","summary":"Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline - MarketWatch","headline":"Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[{"drugName":"AB-452","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"AB-729","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Bayer AG"],"therapeuticFocus":["Hepatitis B","Virology"],"financials":{"source":"sec_edgar+yahoo","revenue":14083000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":14083000,"period":"2025-12-31"},{"value":6171000,"period":"2024-12-31"},{"value":6171000,"period":"2024-12-31"},{"value":18141000,"period":"2023-12-31"},{"value":18141000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":25241000,"rdSpendHistory":[{"period":"2025-12-31","value":25241000},{"period":"2024-12-31","value":54037000},{"period":"2023-12-31","value":73700000},{"period":"2022-12-31","value":84408000}],"sgaSpend":15893000,"operatingIncome":-27051000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-27051000},{"period":"2024-12-31","value":-69974000},{"period":"2023-12-31","value":-78034000},{"period":"2022-12-31","value":-63223000}],"netIncome":-33501000,"netIncomeHistory":[{"period":"2025-12-31","value":-33501000},{"period":"2024-12-31","value":-69920000},{"period":"2023-12-31","value":-72849000},{"period":"2022-12-31","value":-69456000}],"eps":-0.17,"epsHistory":[{"period":"2025-12-31","value":-0.17},{"period":"2024-12-31","value":-0.38},{"period":"2023-12-31","value":-0.44},{"period":"2022-12-31","value":-0.46}],"cash":18008000,"cashHistory":[{"period":"2025-12-31","value":18008000},{"period":"2024-12-31","value":36330000},{"period":"2023-12-31","value":26285000},{"period":"2022-12-31","value":30776000}],"totalAssets":94618000,"totalLiabilities":18042000,"totalDebt":746000,"equity":76576000,"operatingCashflow":-39637000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-39637000},{"period":"2024-12-31","value":-64850000},{"period":"2023-12-31","value":-85936000},{"period":"2022-12-31","value":-35356000}],"capex":-182000,"capexHistory":[{"period":"2024-12-31","value":-182000},{"period":"2023-12-31","value":-1008000},{"period":"2022-12-31","value":-512000},{"period":"2021-12-31","value":-809000}],"freeCashflow":-39637000,"dividendsPaid":null,"buybacks":null,"employees":19,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":3689000,"ebit":-3738000,"ebitda":-3727000,"period":"2025-12-31","revenue":1051000,"epsBasic":null,"netIncome":-3756000,"rdExpense":5006000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-7644000},{"sga":3044000,"ebit":-7719000,"ebitda":-7708000,"period":"2025-09-30","revenue":529000,"epsBasic":-0.04,"netIncome":-7742000,"rdExpense":5778000,"epsDiluted":-0.04,"grossProfit":null,"operatingIncome":-8293000},{"sga":3328000,"ebit":2551000,"ebitda":2562000,"period":"2025-06-30","revenue":10739000,"epsBasic":0.01,"netIncome":2523000,"rdExpense":5498000,"epsDiluted":0.01,"grossProfit":null,"operatingIncome":1913000},{"sga":5832000,"ebit":-24498000,"ebitda":-24168000,"period":"2025-03-31","revenue":1764000,"epsBasic":-0.13,"netIncome":-24526000,"rdExpense":8959000,"epsDiluted":-0.13,"grossProfit":null,"operatingIncome":-13027000},{"sga":4712000,"ebit":-12502000,"ebitda":-12169000,"period":"2024-12-31","revenue":1574000,"epsBasic":null,"netIncome":-12532000,"rdExpense":8810000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-11948000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.1,"netIncome":null,"rdExpense":null,"epsDiluted":-0.1,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.3,"previousClose":4.31,"fiftyTwoWeekHigh":5.1,"fiftyTwoWeekLow":2.94,"fiftyTwoWeekRange":"2.94 - 5.1","fiftyDayAverage":4.41,"twoHundredDayAverage":4.3,"beta":0,"enterpriseValue":760070528,"forwardPE":-26,"priceToBook":10.82,"priceToSales":4.43,"enterpriseToRevenue":3.97,"enterpriseToEbitda":4.9,"pegRatio":0,"ebitda":155136992,"ebitdaMargin":81,"freeCashflow":-88201624,"operatingCashflow":-34356000,"totalDebt":3909000,"debtToEquity":1.5,"currentRatio":54.26,"returnOnAssets":49.2,"returnOnEquity":94.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":5.2,"targetHighPrice":5.58,"targetLowPrice":4.98,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":20.5,"institutionHeldPercent":66.5,"sharesOutstanding":196939679,"floatShares":127077984,"sharesShort":17743389,"shortRatio":8.78,"shortPercentOfFloat":9,"epsTrailing":0.83,"epsForward":-0.17,"revenuePerShare":0.99,"bookValue":0.4,"officers":[{"age":48,"name":"Ms. Lindsay  Androski J.D., M.B.A.","title":"President, CEO & Chairman"},{"age":49,"name":"Mr. Tuan  Nguyen","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Andrew J. Sung","title":"General Counsel"},{"age":74,"name":"Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.","title":"Corporate Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.arbutusbio.com","phone":"267 469 0914"}}